All In Biotech

Drug Trial Radar · NCT06235216

Sacituzumab govitEcan in THYroid Cancers

A Multicenter, Open Label, Two Cohort, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of the Anti-TROP2 Antibody-drug Conjugate Sacituzumab Govitecan in Patients With Advanced Differentiated and Anaplastic Thyroid Neoplasms.

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Sep 13, 2024

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Grupo Espanol de Tumores NeuroendocrinosAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
MFAR; Gilead Sciences
First posted
Jan 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

SETHY is a prospective, multicohort, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory differentiated thyroid carcinoma (DTC) or anaplastic thyroid carcinoma (ATC). The main hypothesis is that treatment with sacituzumab govitecan, a anti-Trophoblast cell surface antigen 2 (TROP-2), could be an effective treatment option for patients with either differentiated and anaplastic thyroid neoplasms because TROP-2 is highly expressed at the membrane of DTC and ATC.

Conditions

  • Differentiated Thyroid Cancer
  • Anaplastic Thyroid Cancer

Interventions

  • Sacituzumab govitecanDrug

    Dose of 10 mg/kg intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: Throughout the study period, approximately 42 months since the inclusion of first patient

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Complexo Hospitalario Universitario de Ferrol

    Ferrol, Spain · Not yet recruiting

  • Institut Catala d´Oncologia (ICO) -Hospitalet

    Hospitalet de Llobregat (Barcelona), Spain · Recruiting

  • Hospital Clínico San Carlos

    Madrid, Spain · Recruiting

  • Hospital Universitario la Paz

    Madrid, Spain · Recruiting

  • Hospital Universitario Ramón y Cajal

    Madrid, Spain · Not yet recruiting

  • MD Anderson Cancer Center Madrid

    Madrid, Spain · Recruiting

  • Hospital General Universitario Morales Meseguer

    Murcia, Spain · Recruiting

  • Hospital Universitario Central de Asturias

    Oviedo, Spain · Recruiting

  • H.U. Marqués de Valdecilla

    Santander, Spain · Recruiting

  • Hospital Universitario Miguel Servet

    Zaragoza, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.